Press release
Key Influencer in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market 2025: Rising Cancer Prevalence Spurs Growth In The Chemotherapy-Induced Nausea And Vomiting (CINV) Market Driver
Chemotherapy Induced Nausea and Vomiting CINV Market Size
The escalating cases of cancer are expected to foster the expansion of the market for chemotherapy-induced nausea and vomiting (CINV). This rise is due to the uncontrolled development and spread of cancer cells in the body. As cancer prevalence increases, there's an increased drive to produce highly effective and specific anti-emetic treatments, which would mitigate CINV, a troubling chemotherapy side effect. This refined focus on CINV management has accelerated the discovery of the mechanisms causing it and the development of new treatments. The American Cancer Society (ACS) expects that by January 2023, there will be 1.9 million new cancer cases (around 5,370 cases daily) and 609,820 cancer deaths (around 1,670 deaths daily) in the U.S. As such, the rise in cancer prevalence is expected to stimulate the CINV market. Additionally, the rising favorable regulatory initiatives are predicted to stimulate the growth of the CINV market. These initiatives are those undertaken by regulatory bodies with the aim to create, implement, or enforce regulations. Such initiatives can be helpful for the improvement of CINV prevention and management and for the development and implementation of guidelines for CINV prevention and management as well. For example, in October 2024, the Food and Drug Administration noted that in 2023, CDER (Center for Drug Evaluation and Research, a division of the U.S. Food and Drug Administration) approved 55 novel drugs for CINV. For this reason, the growth of the CINV market is bolstered by the rise in favorable regulatory initiatives.
Get Your Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report Here:
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report
What growth opportunities are expected to drive the chemotherapy-induced nausea and vomiting (cinv) market's CAGR through 2034?
The market size of chemotherapy-induced nausea and vomiting (CINV) has seen a notable upsurge in recent times. Its projected growth is from $2.92 billion in 2024 to $3.15 billion in 2025, signifying a compound annual growth rate (CAGR) of 7.9%. Increased usage of chemotherapy, enhanced antiemetic agents, clinical guidelines, and patient advocacy are considered as key factors for the significant growth observed in the historic period.
In the forthcoming years, a significant expansion is anticipated in the market size of Chemotherapy-Induced Nausea and Vomiting (CINV), with a projection to reach $4.2 billion by 2029, growing at a Compound Annual Growth Rate (CAGR) of 7.5%. The expansion during the forecast period can be attributed to factors like advancements in personalized medicine, antiemetic agents, telehealth, remote monitoring and health equity initiatives. Major trends influencing the growth during the said period are inclusive of combined antiemetic therapies, supportive care services, digital health tools and survivorship care.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp
What are the most significant trends transforming the chemotherapy-induced nausea and vomiting (cinv) market today?
Prominent firms in the CINV (chemotherapy-induced nausea and vomiting) market are pushing the boundaries with novel product advances, notably fixed intravenous antiemetic, to secure a competitive position. Fixed intravenous antiemetic denotes a set dosage of a drug given via an IV to alleviate or prevent nausea and vomiting, typically employed post-surgery or during chemotherapy. As an example, Glenmark Pharmaceuticals Limited, an Indian pharmaceutical, generics, and over-the-counter (OTC) products manufacturing company, launched AKYNZEO I.V. in January 2023, India's first-ever fixed intravenous antiemetic blend to tackle chemotherapy-induced nausea and vomiting (CINV). The product amalgamates netupitant and palonosetron, aiming to alleviate both immediate and lingering nausea and vomiting phases. With the convenience of a single dose, enhanced comprehensive response rates, and bettered quality of life for cancer sufferers, this product shows substantial promise. Clinical research affirms its particular advantage for patients undergoing highly emetic chemotherapy.
Which growth-oriented segments of the chemotherapy-induced nausea and vomiting (cinv) market are leading the industry's development?
The chemotherapy-induced nausea and vomiting (CINV) market covered in this report is segmented -
1) By Form: Injectables, Oral, Transdermal Patches
2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Class
3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)
4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores
5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications
Subsegments:
1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections
2) By Oral: Tablets, Capsules, Liquid Formulations
3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13031
What regions are leading the charge in the chemotherapy-induced nausea and vomiting (cinv) market?
North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What companies are at the forefront of innovation in the chemotherapy-induced nausea and vomiting (cinv) market?
Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp
What Is Covered In The Chemotherapy-Induced Nausea and Vomiting (CINV) Global Market Report?
• Market Size Forecast: Examine the chemotherapy-induced nausea and vomiting (cinv) market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the chemotherapy-induced nausea and vomiting (cinv) market for a structured understanding.
• Key Players Overview: Analyze major players in the chemotherapy-induced nausea and vomiting (cinv) market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the chemotherapy-induced nausea and vomiting (cinv) market.
• Segment Contributions: Evaluate how different segments drive overall growth in the chemotherapy-induced nausea and vomiting (cinv) market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the chemotherapy-induced nausea and vomiting (cinv) market.
• Industry Challenges: Identify potential risks and obstacles affecting the chemotherapy-induced nausea and vomiting (cinv) market.
• Competitive Landscape: Review strategic developments in the chemotherapy-induced nausea and vomiting (cinv) market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Key Influencer in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market 2025: Rising Cancer Prevalence Spurs Growth In The Chemotherapy-Induced Nausea And Vomiting (CINV) Market Driver here
News-ID: 3906105 • Views: …
More Releases from The Business Research Company
Emerging Innovations Set to Redefine the Sewer Rehabilitation Services Market La …
How Large Is the Sewer Rehabilitation Services Market Anticipated to Become by 2025?
The global market for sewer rehabilitation services has experienced robust expansion lately, projected to increase from a valuation of $42.38 billion in 2024 to $45.14 billion in the subsequent year, reflecting a compound annual growth rate (CAGR) of 6.5%. This historical upward trajectory is primarily fueled by several key factors: escalating levels of urbanization, the ever-aging condition of…
2025-2034 Sea Based C4ISR Market Outlook: Emerging Drivers, Growth Barriers, and …
What Market Size Will the Sea Based C4ISR Sector Reach by 2025?
The maritime C4ISR market experienced substantial expansion lately, projected to climb from a value of $3.0 billion in 2024 to $3.17 billion the following year, reflecting a compound annual growth rate of 5.7%. This upward trend observed over the historical period stems from several factors, including the intensification of naval modernization initiatives, escalating maritime security perils, augmentation in defense…
The Impact of Rapid Urbanization on the Ripening Culture Market: A Key Force Sha …
What Is the Forecasted Size of the Ripening Culture Market by 2025?
The market for ripening cultures has experienced substantial expansion lately, projected to increase from a valuation of $1.46 billion in 2024 to $1.57 billion a year later, demonstrating a consistent yearly growth rate (CAGR) of 7.7%. This upward trajectory during the past period stems from several key factors, including heightened demand for fermented dairy items, greater recognition of the…
Strong Demand Anticipated to Drive Recirculating Chillers Market Toward $2.76 Bi …
How Much Expansion Is Expected in the Recirculating Chillers Market by 2025?
The market encompassing recirculating chillers has seen swift expansion lately, projected to escalate from a value of $1.65 billion in 2024 to $1.83 billion by the ensuing year, reflecting an impressive compound annual growth rate (CAGR) of 11.2%. This upward trajectory during the historical timeframe stems from several factors, including the proliferation of automated systems in industrial procedures, escalating…
More Releases for CINV
Rising Cancer Prevalence Spurs Growth In The Chemotherapy-Induced Nausea And Vom …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size Growth Forecast: What to Expect by 2025?
In recent times, the market encompassing chemotherapy-induced nausea and vomiting treatments has witnessed substantial expansion, projected to increase its valuation from $2.92 billion in 2024 to $3.13 billion in 2025, reflecting a compound annual growth…
CINV Treatment Market to Reach USD 3.9 Billion by 2034
Pune, India, November 11, 2025 - The global Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Market is projected to grow from USD 2.6 billion in 2024 to USD 3.9 billion by 2034, registering a CAGR of 4.1 %, according to Exactitude Consultancy. Rising cancer incidence, increasing chemotherapy adoption, and development of next-generation serotonin (5-HT3) and neurokinin-1 (NK1) receptor antagonists are driving global market expansion.
Download Full PDF Sample Copy of Market Report…
Emerging Trends Influencing The Growth Of The Chemotherapy-Induced Nausea and Vo …
The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size Expected to Be by 2034?
There has been a notable growth in the market size of chemotherapy-induced nausea and vomiting (CINV)…
CINV Existing and Pipeline Drugs Market: Rising Demand for CINV Drugs Owing to I …
CINV drugs are administered to patients suffering from vomiting and nausea that occurs as a side effect of chemotherapy. CINV can hinder the progress of patients undergoing chemotherapy, making it very crucial for oncologists to prescribe the right kind of CINV drugs to alleviate the discomfort. Delayed CINV and acute CINV are the two major subtypes of this condition. While the former occurs up to five days after treatment, the…
CINV Existing and Pipeline Drugs Market : Growing number of patients undergoing …
The growth of the global chemotherapy induced nausea and vomiting (CINV) market will be steered by the growing number of patients undergoing chemotherapy and a number of new drugs expected to be approved in the near future, says Transparency Market Research. In its report, titled “CINV Existing and Pipeline Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020,” the business intelligence firm says that…
CINV Existing and Pipeline Drugs Market : Future Demand and Growth Analysis
Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV). CINV significantly affects the treatment of patients undergoing chemotherapy. Two major subtypes of CINV are acute CINV (occurs within 24 hours of chemotherapy) and delayed CINV (occurs between 24 hours and five days after treatment). Aloxi (palonosetron), Zofran generic (ondansetron), Kytril generic (granisetron), Emend…
